Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035269 · ClinicalTrials.gov registry record · Phase 3
New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 230
- Enrollment target
NCT00035269 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 230 participants.
The verdict
NCT00035269, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 230 participants
- Enrollment target
Study Summary
This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae)
Interventions
- DRUG Antibiotic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2001-12 |
| Est. Completion | 2003-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00035269
The ClinicalTrials.gov registry entry for NCT00035269 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Antibiotic is the first listed.
NCT00035269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00035269 about?
NCT00035269 is a clinical study titled "New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)". This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae)
What is the current status of trial NCT00035269?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 230 participants. The study started on 2001-12. Estimated completion is 2003-05.
What interventions are being tested in trial NCT00035269?
The interventions under investigation include: Antibiotic (DRUG).
Who is sponsoring clinical trial NCT00035269?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.